Co-Diagnostics, Inc. (CODX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 75 | 98 | 34 | 7 | 4 | 1 | 1 | 1 |
| Operating profit | $m | -31 | -30 | ||||||
| Net profit | $m | 42 | 37 | -14 | -35 | -38 | -47 | -47 | - |
| EPS reported | $ | -35.25 | -26.72 | ||||||
| Operating cashflow per share | $ | -21.90 | -6.29 | ||||||
| Capex per share | $ | 0.53 | 0.09 | ||||||
| FCF per share | $ | -22.43 | -6.37 | ||||||
| Free cash flow | $m | -30 | -27 | ||||||
| Net debt | $m | -11 | -4 | ||||||
| Book value equity | $m | 21 | 13 | ||||||
| Book value per share | $ | 15.51 | 2.95 | ||||||
| Number of shares | m | 1.33 | 4.31 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.33 | 0.53 | ||||||
| P/S LTM | x | 10.83 | 9.35 | ||||||
| P/FCF LTM | x | -0.23 | -0.25 | ||||||
| EV/EBITDA LTM | x | 0.08 | 0.08 | ||||||
| EV/Sales LTM | x | -6.27 | -0.77 | ||||||
| Earnings Yield LTM | % | -6.95% | -9.41% | ||||||
| FCF Yield | % | -442.42% | -407.33% | ||||||
| Quality | |||||||||
| ROE | % | -227.33% | -210.99% | ||||||
| ROIC | % | -1.38% | -2.00% | ||||||
| Operating margin | % | -50.26% | -41.70% | ||||||
| Gross margin | % | +64.28% | +8.07% | ||||||
| FCF/Sales | % | -4793.2% | -3808.0% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -84.10% | -81.57% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -24.13 | -15.27 | ||||||
| Net Debt/EBITDA | x | 0.22 | 0.04 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +8.52% | 0.00% | ||||||
| Net debt/Equity | x | -0.55 | -0.29 | ||||||
| Gross debt/equity | x | 0.06 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free